G. Bollag
Molecular Biology · 2004–2019
A researcher in the Science corpus: 9 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 121 citations into it
Whom G. Bollag trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts G. Bollag overall
Papers from G. Bollag's perspective
Ordered by how strongly the researchers G. Bollag trusts endorse each paper. Same corpus, a different order for every researcher.
- Mutations of the BRAF gene in human cancer (Nature)
- Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
- The RAF proteins take centre stage (Nature reviews. Molecular cell biology)
- High frequency of BRAF mutations in nevi (Nature Genetics)
- Targeting RAS signalling pathways in cancer therapy (Nature Reviews. Cancer)
- Regulation of Raf-1 by direct feedback phosphorylation. (Molecules and Cells)
- Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. (Cancer Cell)
- Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. (Genes & Development)
- Somatic activation of the K-ras oncogene causes early onset lung cancer in mice (Nature)
- The Guanine Nucleotide-Binding Switch in Three Dimensions (Science)
Their papers
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma (2010) — 1,767 citations
- RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF (2010) — 1,791 citations
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis (2004) — 3,992 citations
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity (2008) — 1,352 citations
- Hyperactive Ras in developmental disorders and cancer (2007) — 1,002 citations
- Vemurafenib: the first drug approved for BRAF-mutant cancer (2012) — 779 citations
- Germline KRAS mutations cause Noonan syndrome (2006) — 727 citations
- Hyperactive Ras in developmental disorders and cancer (2007) — 649 citations
- Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model (2019) — 721 citations